Cardiovascular Biomarkers: Players, products and prospects (Volume III)

Date: August 22, 2008
Pages: 120
Price:
US$ 1,040.00
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: CF458F73C95EN
Leaflet:

Download PDF Leaflet

Cardiovascular Biomarkers: Players, products and prospects (Volume III)
In 2007, the cardiovascular biomarker market accounted for an estimated 23% of biomarker revenues to generate over US$1.3 billion with the majority of revenues derived from biomarker discovery and molecular diagnostics. The market has yet to reach the maturity of the oncology biomarker market, but over the coming years the importance of genetic markers and companion diagnostics will grow. By 2015, the estimated market value will be US$6.6 billion, with biomarker discovery being the largest component.

One of the largest markets for cardiovascular biomarkers lies in the diagnosis of acute coronary syndromes in patients presenting with acute signs and symptoms, such as shortness of breath or chest pain.

For example, Troponin is well established as a diagnostic marker of myocardial infarction and has been described as the cornerstone of diagnosis for the condition. However, the marker has a major limitation: troponin levels only rise six to eight hours after a myocardial ischaemia. The search for new diagnostic biomarkers for use in the acute setting has focused on the identification of earlier markers of infarction. These include ischaemia modified albumin (IMA) as well as potential markers, heart fatty acid binding protein and glycogen phosphorylase isoenzyme BB (GPBB). In addition, some of the leading providers are suggesting that panels of cardiac markers are most useful for diagnosis in acute settings. Examples include Biosite’s (now part of Inverness Medical Innovations) CardioProfiler Triage panel. This is a PoC diagnostic that measures a number of markers including Troponin I, CK-MB, myoglobin and BNP. New multi-marker panels are also under development. These include an index score panel for the diagnosis of peripheral artery disease (VASCLIR, Vermillion). The panel evaluates ß-2-microglobulin, cystatin C, hsCRP and glucose to create an index score and is currently in clinical trials.

Screening patients for prediction of future cardiovascular disease is currently the second major market for cardiovascular biomarkers. These markers include lipid biomarkers (e.g. LDL, HDL, triglycerides, LDL particle number and lipoprotein concentrations) or inflammatory biomarkers (e.g. CRP or Lp-PLA2). Lipid profiles are well-established as indicators of future cardiovascular risk that can be reduced through the use of lipid-lowering therapies such as statins.

Questions, Questions
  • What clinical studies are CardioDx currently engaged in?
  • What approach is deCODE Genetics taking in its research?
  • Which pharmaceutical companies are utilising Entelos predictive biostimulation technology?

Focus on...market potential

In 2007, the cardiovascular biomarker market accounted for and estimated 23% of biomarker revenues generating over US$1.3 billion, with the majority of revenues derived from biomarker discovery and molecular diagnostics. The market has yet to reach the maturity of the oncology biomarker market, but will grow in the short term with the introduction of new, proprietary markers for acute coronary syndromes. Over the coming years, the importance of genetic markers and companion diagnostics will grow.

By 2015, we estimate the global cardiovascular biomarker market will account for around one third of global biomarker sales and will be worth up to US$6.6 billion as it becomes more mature; driven by growth in clinical biomarkers, the development of targeted therapies and associated companion diagnostics, discovery and validation of genetic markers of cardiovascular risk and reimbursement of pharmacogenomic and prognostic tests.

Companies Analysed

- Abbott Diagnostics
- Atherotech
- Affymetrix
- Beckman Coulter
- Berkeley HeartLab
- BG Medicine
- CardioDx
- Celera
- CIS Biotech
- Clinical Data
- Compugen
- Critical Diagnostics
- deCODE Genetics
- diaDexus
- Entelos
- FoxHollow Technologies
- GE Healthcare
- Genomas
- Inverness Medical Innovations
- Jurilab
- Laboratory Corporation of America
- Lipomics Technologies
- LipoScience
- Nanosphere Inc
- Osmetech Molecular Diagnostics
- PrognostiX
- Quest Diagnostics
- Roche Diagnostics
- Siemens Medical Solutions
- Singulex
- SuperArray Bioscience Corporation
- Vermillion
- Zora Biosciences OY
Skip to top


Ask Your Question

Cardiovascular Biomarkers: Players, products and prospects (Volume III)
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: